Repligen Co. (NASDAQ:RGEN) Shares Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC lifted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 66.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,000 shares of the biotechnology company's stock after purchasing an additional 10,000 shares during the period. Repligen comprises about 1.6% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 28th largest position. Sivik Global Healthcare LLC's holdings in Repligen were worth $3,721,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Toronto Dominion Bank grew its position in shares of Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock worth $656,000 after buying an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock worth $982,000 after purchasing an additional 89 shares during the last quarter. Ballentine Partners LLC grew its stake in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company's stock valued at $269,000 after purchasing an additional 105 shares during the last quarter. Diversified Trust Co raised its holdings in Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after purchasing an additional 106 shares in the last quarter. Finally, CWM LLC lifted its position in shares of Repligen by 36.3% during the third quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after buying an additional 114 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on RGEN. UBS Group dropped their target price on Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Benchmark reiterated a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Wolfe Research initiated coverage on Repligen in a research report on Thursday. They issued a "peer perform" rating for the company. Finally, Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Price Performance

Shares of NASDAQ RGEN traded down $8.04 on Thursday, hitting $142.43. The company's stock had a trading volume of 748,275 shares, compared to its average volume of 660,235. The stock has a 50 day moving average of $141.59 and a 200-day moving average of $144.78. The company has a market capitalization of $7.98 billion, a price-to-earnings ratio of -389.94, a price-to-earnings-growth ratio of 4.27 and a beta of 0.96. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. During the same period last year, the company earned $0.23 EPS. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, research analysts predict that Repligen Co. will post 1.45 EPS for the current year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.